| Literature DB >> 28959553 |
Zeba Farooqui1, Mohammad Afsar1, Sana Rizwan1, Aijaz Ahmed Khan2, Farah Khan1.
Abstract
Cisplatin (CP) is a potent anti-cancer drug widely used against solid tumors. However, it exhibits pronounced adverse effects including hepatotoxicity. Several strategies were attempted to prevent CP hepatotoxicity but were not found suitable for therapeutic application. Nigella sativa has been shown to prevent/reduce the progression of certain type of cardiovascular, kidney and liver diseases. Present study investigates whether N. sativa oil (NSO) can prevent CP induced hepatotoxic effects. Rats were divided into four groups viz. control, CP, NSO and CPNSO. Animals in CPNSO and NSO group were administered NSO (2 ml/kg bwt, orally) with or without single hepatotoxic dose of CP (6 mg/kg bwt, i.p.) respectively. CP hepatotoxicity was recorded by increased serum ALT and AST activities. CP treatment caused oxidant/antioxidant imbalances as reflected by increased lipid peroxidation and decreased enzymatic and non-enzymatic antioxidants. Furthermore, the activities of various carbohydrate metabolism and membrane enzymes were altered by CP treatment. In contrast, NSO administration to CP treated rats, markedly ameliorated the CP elicited deleterious alterations in liver. Histopathological observations showed extensive liver damage in CP treated animals while greatly reduced tissue injury in CPNSO group. In conclusion, NSO appears to protect CP induced hepatotoxicity by improving energy metabolism and strengthening antioxidant defense mechanism.Entities:
Keywords: ACPase, acid phosphatase; ALP, alkaline phosphatise; ALT, alanine aminotransferase; AST, aspartate aminotransferases; Antioxidant; BBM, brush border membrane; BBMV, BBM vesicles; BUN, blood urea nitrogen; CAT, catalase; CP, cisplatin; Carbohydrate metabolism; Chl, cholesterol; Cisplatin; FBPase, fructose 1,6; G6PDH, glucose 6-phosphate dehydrogenase; G6Pase, glucose 6-phosphatase; GGTase, γ-glutamyl transferase; GR, glutathione reductase; GSH, glutathione; GSHPx, glutathione peroxidise; GST, glutathione S-transferase; Glc, glucose; H2O2, hydrogen peroxide; HK, hexokinase; LAP, leucine aminopeptidase; LDH, lactate dehydrogenase; LPO, lipid peroxidation; MDA, malondialdehyde; MDH, malate dehydrogenase; ME, malic enzyme; NADP, nicotinamide adenine dinucleotide phosphate; NADPH, nicotinamide adenine dinucleotide phosphate reduced; NSO, Nigella sativa oil; Nigella sativa oil; PLs, phospholipids; PUFA, polyunsaturated fatty acids; Pi, inorganic phosphate; ROS, reactive oxygen species; SH, sulfhydryl; SOD, superoxide dismutase; Scr, serum creatinine; TCA, tricarboxylic acid; TR, thioredoxin reductase; μm, micrometer
Year: 2016 PMID: 28959553 PMCID: PMC5615832 DOI: 10.1016/j.toxrep.2016.02.004
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Effect of NSO on serum parameters with/without CP treatment.
| Enzymes/parameters | ALT (IU/L) | AST (IU/L) | Cholesterol (mg/dl) | Phospholipid (mg/dl) |
|---|---|---|---|---|
| Control | 45.65 ± 2.55 | 26.65 ± 0.25 | 86.85 ± 2.64 | 209.68 ± 7.56 |
| CP | 74.12 ± 2.22 | 41.60 ± 0.60 | 112.64 ± 3.06* (+30%) | 260.15 ± 1.78 |
| NSO | 34.65 ± 2.08 | 27.25 ± 1.35 (+2%) | 61.59 ± 1.68 | 196.97 ± 3.1 (−6%) |
| CPNSO | 35.35 ± 3.05 | 30.41 ± 1.36 | 81.44 ± 0.81 | 210.48 ± 3.57 |
CP: cisplatin treated; NSO: Nigella sativa oil administered; CPNSO: Nigella sativa oil administered + cisplatin treated; ALT: alanine aminotransferases; AST: aspartate aminotransferases. Results are mean ± SEM for three different experiments. Values in parenthesis represent percent change from control.
Significantly different from control.
Significantly different from CP at p < 0.05 by one way ANOVA.
Effect of NSO on membrane and lysosomal enzymes in liver homogenate with/without CP treatment.
| Enzyme | ALP (μmol/mg protein/h) | GGTase (μmol/mg protein/h) | LAP (μmol/mg protein/h) | ACPase (μmol/mg protein/h) |
|---|---|---|---|---|
| Control | 8.60 ± 0.212 | 1.17 ± 0.087 | 0.76 ± 0.046 | 2.75 ± 0.214 |
| CP | 5.77 ± 0.125 | 0.76 ± 0.091 | 0.38 ± 0.017* (−50%) | 4.48 ± 0.240 |
| NSO | 9.20 ± 0.481 (+6%) | 1.22 ± 0.044 (+4%) | 0.91 ± 0.032 | 2.17 ± 0.160 |
| CPNSO | 8.39 ± 0.133 | 1.09 ± 0.043 | 0.71 ± 0.032** (−6%) | 3.22 ± 0.111 (+17%) |
CP: cisplatin treated; NSO: Nigella sativa oil administered; CPNSO: Nigella sativa oil administered + cisplatin treated; ALP: alkaline phosphatase; GGTase: γ—glutamyl transferase; LAP: leucine amonipeptidase; ACPase: acid phosphatase. Results (specific activity expressed as μmoles/mg protein/h) are mean ± SEM for three different experiments. Values in parenthesis represent the percent change from control.
Significantly different from control.
Significantly different from CP at p < 0.05 by one way ANOVA.
Effect of NSO on activities of carbohydrate metabolic enzymes in liver homogenate with/without CP treatment.
| Enzyme | HK (μmol/mg protein/h) | LDH (μmol/mg protein/h) | MDH (μmol/mg protein/h) | G6Pase (μmol/mg protein/h) | FBPase (μmol/mg protein/h) | G6PDH (μmol/mg protein/h) | ME (μmol/mg protein/h) |
|---|---|---|---|---|---|---|---|
| Control | 1.36 ± 0.073 | 0.43 ± 0.161 | 2.21 ± 0.03 | 0.20 ± 0.018 | 0.746 ± 0.081 | 0.034 ± 0.003 | 0.049 ± 0.006 |
| CP | 1.73 ± 0.079 (+27%) | 0.59 ± 0.019 | 0.85 ± 0.035 | 0.133 ± 0.008 | 0.64 ± 0.019 | 0.012 ± 0 | 0.096 ± 0.003 |
| NSO | 1.25 ± 0.032 (−8%) | 0.41 ± 0.020 (−5%) | 1.82 ± 0.158 (−17%) | 0.178 ± 0.007 | 0.78 ± 0.037 (+4%) | 0.035 ± 0.003 (+2%) | 0.039 ± 0.003 (−20%) |
| CPNSO | 1.35 ± 0.072 | 0.50 ± 0.019 (+16%) | 1.25 ± 0.064** (−43%) | 0.155 ± 0.005 (−22%) | 0.75 ± 0.058** (+0.536%) | 0.020 ± 0.001** (−41%) | 0.041 ± 0.002 |
CP: cisplatin treated; NSO: Nigella sativa oil administered; CPNSO: Nigella sativa oil administered + cisplatin treated; HK: hexokinase; LDH: lactate dehydrogenase; MDH: malalte dehydrogenase; G6Pase: glucose-6-phosphatase; FBPase: fructose-1, 6-bisphosphatase; G6PDH: glucose-6-phosphatase dehydrgenase; ME: malic enzyme. Results (specific activity expressed as μmoles/mg protein/hr) are mean ± SEM for three different experiments. Values in parenthesis represent percent change from control.
Significantly different from control.
Significantly different from CP at p < 0.05 by one way ANOVA.
Effect of NSO on non-enzymatic antioxidant parameters in liver homogenate with/without CP treatment.
| Parameters | Lipid peroxidation (nmol/g tissue) | Total SH (μmol/g tissue) | GSH (μmol/g tissue) |
|---|---|---|---|
| Control | 258.72 ± 2.00 | 19.21 ± 0.744 | 0.98 ± 0.035 |
| CP | 335.46 ± 5.31* (+229%) | 15.55 ± 0.824 | 0.55 ± 0.039 |
| NSO | 210.97 ± 8.03 | 20.88 ± 0.270 (+8%) | 0.87 ± 0.035 (−11%) |
| CP NSO | 274.03 ± 3.28 | 17.94 ± 0.603 (−6%) | 0.79 ± 0.054 |
CP: cisplatin treated; NSO: Nigella sativa oil administered; CPNSO: Nigella sativa oil administered + cisplatin treated; GSH: glutathione. Results are mean ± SEM for three different experiments. Values in parenthesis represent percent change from control.
Significantly different from control.
Significantly different from CP at p < 0.05 by one way ANOVA.
Effect of NSO on enzymatic antioxidant parameters in liver homogenate with/without CP treatment.
| Enzyme | SOD (units/mg protein) | CAT (μmol/mg protein/min) | GSH-Px (μmol/mg protein/min) | TR (μmol/mg protein/min) | GR (μmol/mg protein/min) | GST (μmol/mg protein/min) |
|---|---|---|---|---|---|---|
| Control | 39.07 ± 1.55 | 24.39 ± 1.056 | 0.054 ± 0.003 | 0.066 ± 0.004 | 0.036 ± 0.003 | 0.58 ± 0.041 |
| CP | 27.32 ± 0.88* (−30%) | 13.71 ± 0.266* (−43%) | 0.035 ± 0.001* (−35%) | 0.025 ± 0.002* (−62%) | 0.020 ± 0.003* (−44%) | 0.34 ± 0.01* (−41%) |
| NSO | 45.06 ± 2.94 (+15%) | 24.77 ± 0.543 (+1%) | 0.052 ± 0 (−4%) | 0.044 ± 0.002 (−33%) | 0.033 ± 0.003 (−8%) | 0.576 ± 0.026 (−1%) |
| CPNSO | 37.45 ± 1.05** (−4%) | 21.39 ± 0.652** (−12%) | 0.046 ± 0.001** (−14%) | 0.038 ± 0.005 (−42%) | 0.032 ± 0.003** (−22%) | 0.52 ± 0.013** (−2%) |
CP: cisplatin treated; NSO: Nigella sativa oil administered; CPNSO: Nigella sativa oil administered + cisplatin treated; SOD: superoxide dismutase; CAT: catalase; GSH-Px: glutathione peroxidase; TR: theoredoxin reductase; GR: glutathione reductase; GST: glutathione- S- transferase. Results are mean ± SEM for three different experiments. Values in parenthesis represent percent change from control.
*Significantly different from control.
**Significantly different from CP at p < 0.05 by one way ANOVA.
Fig. 1Histopathology of rat liver showing hepatocytes () and sinusoids () in control (A) with normal histoarchitecture of hepatocytes and intact hepatic cord whereas in CP treated group (B) disorganised hepatic cords, necrosis of hepatocytes and congested sinusoids were observed. NSO administered group (C) shows well preserved conditions of both, hepatocytes and sinusoids very similar to control. CPNSO group (D) shows fairly intact histoarchitecture, hepatic cords and no obvious necrosis. However, sinusoids appear moderately congested as compared to control. H & E stain, initial magnification ×400 scale bar = 50 μm.